http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
ABLYNX TO PRESENT AT THE 36th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
NOTICE IN RELATION TO WAIVER OF LOCK-UP RESTRICTION
-
ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB
-
Ablynx NV (ABLX) Reports Additional Results from Phase III HERCULES Study with Caplacizumab for Treatment of aTTP
-
ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP
-
ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
Ablynx NV (ABLX) Says Results from Hercules Study of Caplacizumab Selected for Late-Breaker at ASH
-
RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING
-
ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON AND PARIS
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
CORRECTION OF PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN LONDON
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE
-
ABLYNX WILL ANNOUNCE ITS 2017 HALF YEAR RESULTS WITH WEBCAST ON 24 AUGUST 2017
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX AND SANOFI ENTER INTO A STRATEGIC COLLABORATION TO DEVELOP NANOBODY PRODUCT CANDIDATES FOCUSED ON IMMUNE-MEDIATED INFLAMMATORY DISEASES
-
ABLYNX PROPOSES APPOINTMENT OF MRS HILDE WINDELS AS A NEW INDEPENDENT DIRECTOR
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA
-
ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS
-
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
-
ABLYNX TO PRESENT ADDITIONAL DATA FOR ITS ANTI-IL-6R NANOBODY, VOBARILIZUMAB, AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY
-
ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER
-
NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT
-
ABLYNX TO PRESENT AT UPCOMING USA INVESTOR CONFERENCES
-
ABLYNX REPORTS FINANCIAL RESULTS FOR THE FIRST THREE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE
-
ABLYNX COMPLETES PATIENT RECRUITMENT IN ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF aTTP
-
ABLYNX ANNOUNCES WARRANT EXERCISE
-
ABLYNX'S PARTNER, MERCK KGaA, HAS PRESENTED NEW DATA FROM A PHASE Ib PSORIASIS STUDY OF THE BI-SPECIFIC ANTI-IL-17A/F NANOBODY AT THE ANNUAL AAD CONFERENCE
